Genmab Stock (NASDAQ:GMAB), Trade Ideas

Genmab

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Penny Stocks

Small Cap

Markets

AVBP

GMAB

NUVB

Key Takeaways:


	Cancer treatment maker ProfoundBio announced it will be purchased by Denmark’s Genmab for $1.8 billion
	The deal is the fourth acquisition of a China-related innovative drugmaker by a foreign company in the last four months


By Doug Young

ProfoundBio Discovers The Joys Of Having A Wealthy Owner

Gavel law Image by Okan Caliskan from Pixabay

Analyst Color

Biotech

Equities

Large Cap

News

Health Care

Reiteration

Legal

Movers

Trading Ideas

General

Genmab&#39;s legal update on Darzalex: Arbitrator dismisses bid for milestone payments. Despite this, diverse revenue sources, including royalty agreements, contribute to strong growth.

What&#39;s Going On With Danish Healthcare Firm Genmab Stock?

Pre-Market Outlook

ABNB

GPRO

KNTK

LCID

ORCL

U.S. stock futures were higher this morning, with the Dow Jones futures gaining over 50 points on Tuesday.

Oracle Reports Weak Sales, Joins Kinetik, Lucid Group And Other Big Stocks Moving Lower In Tuesday&#39;s Pre-Market Session

Genmab A/S

The late <a href="https://www.benzinga.com/personal-finance/24/04/38158576/charlie-munger-said-find-a-way-to-get-your-hands-on-100-000-even-if-it-means-walking-everywhere-">Charlie Munger</a> once said that the first $100,000 is a critical stepping stone in building wealth — a sentiment echoed by many financial experts. 
However, a Reddit user recently sparked a discussion on the r/FinancialPlanning subreddit by questioning the perceived ease of growing net worth from $100,000 to $1 million.&nbsp;
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/are-you-rich-advisor">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/red-ventures"> The percentage may shock you</a>.</li>
</ul>
The 26-year-old user, expressing diligence in their financial strategy, is already maxing out their 401(k) and Roth individual retirement account (IRA) contributions and has set aside emergency funds. Additionally, they invest $1,000 monthly in an S&amp;P 500 exchange-traded fund (ETF) through a brokerage account. Despite these efforts, they wondered why it is said to be "easy" to escalate from $100,000 to $1 million and sought guidance on the next steps to take to make it happen in five to 10 years.&nbsp;
The Reddit community responded with a mix of encouragement and realism. The core advice centered on the principle of compound interest, the financial phenomenon where earnings on an investment generate their own earnings over time. Users explained that, given time and a consistent rate of return, the original investment sum could see exponential growth. For example, with an 8% return rate, $100,000 could surpass $200,000 in a decade and potentially reach $1 million in 30 years, as shown in the breakdown provided by a user in the thread.
It was also noted that this calculation doesn't <a href="https://www.benzinga.com/personal-finance/24/02/36957443/the-majority-of-americans-dont-feel-financially-secure-and-believe-they-need-to-earn-233-000-a-y">factor in inflation</a>, which could significantly reduce the real value of future money. Inflation at 3% would adjust the real return to 5%, meaning the growth of the investment could be less significant than the nominal figures suggest.
Trending: The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?
Another user reminded the original poster of the importance of market volatility. <a href="https://www.benzinga.com/personal-finance/24/04/38275323/warren-buffett-warns-dont-watch-the-market-closely-urges-not-to-obsessively-check-stock-prices-i">Investment portfolios can fluctuate widely</a> with market conditions, which might affect both the timeline and the psychological comfort of the investor. Staying the course despite market downturns is crucial to achieving long-term financial goals.
Some users suggested diversifying beyond ETFs and contributing to the investments regularly. This would help mitigate risk and potentially increase returns. Considering alternative investments like real estate or bonds could provide additional income streams and further diversification.
A point was made about the net present value of money, prompting investors to consider what their financial goals truly are — whether having $100,000 now is more valuable than $1 million in the future, taking into account personal circumstances and goals.
Trending: 82% of Americans aren&#8217;t using<a href="https://www.benzinga.com/money/public-hys"> this government secured 5% passive income stream</a>, are you one of them?
The Reddit thread paints a picture of careful financial planning that involves understanding the impact of time, consistent investing and diversification while also being mindful of economic factors like inflation and market volatility. The path to growing wealth significantly is shown to be more complex than a simple multiplication of funds and is unique to each person's situation and resilience in the face of market ups and downs.
Whether you're just starting to save, already have $100,000 or are on the brink of hitting $1 million, <a href="https://www.benzinga.com/money/smartasset">talking to a financial adviser</a> can be a smart move. They offer tailored advice that matches your unique financial situation and goals, helping you navigate investment strategies, tax implications and potential economic challenges. With their guidance, you can craft a comprehensive plan that boosts your chances of achieving your financial milestones, no matter where you're starting.
Read Next:
<ul>
<li>Americans got swindled out of $24.6 billion in the last 3 years —<a href="https://www.benzinga.com/money/advisor-adv"> Which high profile ponzi scheme was endorsed by millionaires?</a></li>
<li>The average American would have how much in their bank account if they started saving in 2010 with today&#8217;s high yield savings account rates?<a href="https://www.benzinga.com/money/public-hys-avgamerican"> The numbers may shock you</a>.</li>
</ul>

Personal Finance

'How Is Turning $100,000 Into $1 Million Easy?' 26-Year-Old Asks Strangers Why Net Worth Explodes From There  — Here's What They Said

Rogers Communications&nbsp;Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCI#NYSE">RCI</a>)&nbsp;reported&nbsp;fiscal first-quarter 2024 revenue growth of 28%&nbsp;year-over-year&nbsp;to $3.64 billion (4.90 billion Canadian dollars), beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/g38399718/rogers-communications-reports-first-quarter-2024-results" rel="noreferrer noopener">consensus of $3.58 billion</a>.
The adjusted EPS of $0.73 (CA$0.99) beat the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $0.72</a>.
Total service revenue grew 31% Y/Y to CA$4.36 billion on higher revenue growth in the Cable and Wireless businesses.
Wireless service revenue increased by 9% Y/Y, mainly aided by the cumulative impact of growth in the mobile phone subscriber base and revenue from Shaw Mobile subscribers.
Wireless equipment revenue increased by 4%, primarily due to a continued shift in the product mix towards higher-value devices.
Cable service revenue rose 94% Y/Y, aided by the acquisition of Shaw. Media revenue decreased by 5%&nbsp;Y/Y,&nbsp;due to lower subscriber revenue.
Rogers attracted 98,000 net postpaid mobile phone subscribers, up 3.2% Y/Y, with a churn of 1.10%.
Adjusted EBITDA increased 34% Y/Y to&nbsp;CA$2.21&nbsp;billion, with margins increasing 210 bps to 45.2% due to improving synergies and efficiencies.
Rogers generated CA$586 million in free cash flow for the quarter, up 58% Y/Y. It held CA$0.8 billion in cash and cash equivalents as&nbsp;of March-end. Capital expenditure rose 19% Y/Y to CA$1.06 billion.
Dividend:&nbsp;The company declared&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/g38399673/rogers-communications-declares-50-cents-per-share-quarterly-dividend" rel="noreferrer noopener">a&nbsp;quarterly dividend</a>&nbsp;of 50 cents&nbsp;on each of its outstanding Class B Non-Voting&nbsp;shares&nbsp;and Class A Voting shares.
&#8220;We continued to deliver industry-leading growth in the first quarter, our ninth straight quarter of growth and momentum,&#8221; said Tony Staffieri, President and CEO.
Rogers Communications stock lost 20% in the last 12 months. Investors can gain exposure to the stock via&nbsp;First Trust VL Dividend&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FVD#NYSE">FVD</a>) and&nbsp;First Trust NASDAQ Technology Dividend Index Fund&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDIV#NASDAQ">TDIV</a>).
Price Action:&nbsp;RCI shares are trading lower by 3.7% at $38.12 at&nbsp;the last check Wednesday.

Earnings

Dividends

First Trust Value Line Dividend Index Fund ETF

TDIV

Rogers Comm's Q1 Earnings Exceed Expectations Driven by Wireless Strength

WIIM

BTCM

CLSK

COIN

MSTR

Shares of crypto-related stocks are trading lower amid a pullback in the price of Bitcoin.

Lennox shares are trading lower after the company reported mixed Q1 financial results.

<h3>Gainers</h3>
<ul>
<li>Chicken Soup for the Soul (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSSE#NASDAQ">CSSE</a>) stock moved upwards by 140.2% to $0.37 during Wednesday's regular session. The company's market cap stands at $11.8 million. As per the press release, Q4 earnings came out 3 days ago. </li>
<li>Chicken Soup for the Soul (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSSEP#NASDAQ">CSSEP</a>) shares moved upwards by 133.33% to $0.98. </li>
<li>WiMi Hologram Cloud (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WIMI#NASDAQ">WIMI</a>) stock rose 43.36% to $1.04. The company's market cap stands at $90.1 million. </li>
<li>HWH International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HWH#NASDAQ">HWH</a>) shares rose 15.56% to $1.75. The market value of their outstanding shares is at $28.3 million. </li>
<li>Bilibili (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BILI#NASDAQ">BILI</a>) shares increased by 11.35% to $12.79. The market value of their outstanding shares is at $5.2 billion. </li>
<li>Chicken Soup for the Soul Entertainment, Inc. - 9.50% Notes due 2025 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSSEN#NASDAQ">CSSEN</a>) stock increased by 9.58% to $4.0. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Cineverse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNVS#NASDAQ">CNVS</a>) shares decreased by 14.8% to $0.81 during Wednesday's regular session. The company's market cap stands at $10.7 million. </li>
<li>Direct Digital Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRCT#NASDAQ">DRCT</a>) stock fell 13.42% to $6.0. The market value of their outstanding shares is at $86.0 million. </li>
<li>Sound Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOGP#NASDAQ">SOGP</a>) shares decreased by 9.88% to $2.83. The market value of their outstanding shares is at $14.9 million. </li>
<li>Travelzoo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TZOO#NASDAQ">TZOO</a>) stock decreased by 8.9% to $8.5. The company's market cap stands at $112.2 million. As per the press release, Q1 earnings came out today. </li>
<li>Loop Media (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LPTV#AMEX">LPTV</a>) stock declined by 8.78% to $0.32. The company's market cap stands at $22.5 million. </li>
<li>Scienjoy Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SJ#NASDAQ">SJ</a>) shares decreased by 8.73% to $0.73. The company's market cap stands at $29.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-communication-services-stocks/" title="www.benzinga.com/money/best-communication-services-stocks/">www.benzinga.com/money/best-communication-services-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BILI

CNVS

CSSE

CSSEN

CSSEP

DRCT

LPTV

SOGP

TZOO

WIMI

12 Communication Services Stocks Moving In Wednesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Catheter Precision (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#AMEX">VTAK</a>) shares moved upwards by 27.8% to $0.58 during Wednesday's regular session. The company's market cap stands at $4.4 million. </li>
<li>Prenetics Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>) stock moved upwards by 26.25% to $5.77. The company's market cap stands at $70.4 million. </li>
<li>Alterity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHE#NASDAQ">ATHE</a>) stock rose 15.02% to $2.45. The market value of their outstanding shares is at $21.3 million. </li>
<li>Immutep (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMMP#NASDAQ">IMMP</a>) shares increased by 13.54% to $2.85. The market value of their outstanding shares is at $338.8 million. </li>
<li>CareMax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMAX#NASDAQ">CMAX</a>) shares rose 12.89% to $3.94. The market value of their outstanding shares is at $14.9 million. </li>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) stock moved upwards by 12.84% to $0.04. The market value of their outstanding shares is at $4.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) shares decreased by 38.2% to $0.47 during Wednesday's regular session. The company's market cap stands at $12.5 million. </li>
<li>Evotec (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) shares decreased by 31.9% to $5.21. The market value of their outstanding shares is at $1.8 billion. As per the news, the Q4 earnings report came out today. </li>
<li>Vaxxinity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VAXX#NASDAQ">VAXX</a>) stock fell 26.51% to $0.15. The market value of their outstanding shares is at $18.6 million. </li>
<li>Addex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADXN#NASDAQ">ADXN</a>) shares fell 18.9% to $15.2. The market value of their outstanding shares is at $16.2 million. As per the news, the Q4 earnings report came out 4 days ago. </li>
<li>Kiora Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPRX#NASDAQ">KPRX</a>) stock declined by 15.41% to $0.49. The market value of their outstanding shares is at $12.8 million. </li>
<li>Sunshine Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) shares decreased by 14.87% to $1.03. The market value of their outstanding shares is at $1.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADXN

Alterity Therapeutics Limited - American Depositary Shares

ATHE

CMAX

GCTK

IMMP

Kiora Pharmaceuticals, Inc. - Common Stock

KPRX

SBFM

SINT

VAXX

VTAK

12 Health Care Stocks Moving In Wednesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Lichen China (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LICN#NASDAQ">LICN</a>) shares moved upwards by 49.1% to $0.84 during Wednesday's regular session. The company's market cap stands at $22.8 million. </li>
<li>Babcock &amp; Wilcox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BW#NYSE">BW</a>) stock increased by 23.9% to $1.14. The company's market cap stands at $101.6 million. </li>
<li>Solidion Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STI#NASDAQ">STI</a>) stock moved upwards by 22.32% to $1.86. The company's market cap stands at $161.5 million. </li>
<li>Skillsoft (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKIL#NYSE">SKIL</a>) shares increased by 19.66% to $6.83. The company's market cap stands at $55.3 million. </li>
<li>C3is (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CISS#NASDAQ">CISS</a>) stock moved upwards by 13.54% to $1.43. The company's market cap stands at $2.7 million. </li>
<li>Perma-Pipe Inlt Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPIH#NASDAQ">PPIH</a>) stock increased by 12.28% to $7.86. The company's market cap stands at $62.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Jayud Global Logistics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JYD#NASDAQ">JYD</a>) stock decreased by 14.9% to $0.89 during Wednesday's regular session. The market value of their outstanding shares is at $18.8 million. </li>
<li>Greenwave Tech Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GWAV#NASDAQ">GWAV</a>) shares decreased by 11.74% to $0.06. The company's market cap stands at $2.7 million. </li>
<li>SolarMax Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMXT#NASDAQ">SMXT</a>) shares fell 11.7% to $8.08. The company's market cap stands at $365.5 million. </li>
<li>AERWINS Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWIN#NASDAQ">AWIN</a>) stock declined by 11.12% to $2.96. The market value of their outstanding shares is at $2.1 million. </li>
<li>Northann (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NCL#AMEX">NCL</a>) shares fell 10.77% to $0.5. The market value of their outstanding shares is at $10.6 million. </li>
<li>KULR Tech Gr (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KULR#AMEX">KULR</a>) shares fell 10.76% to $0.46. The company's market cap stands at $79.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AWIN

CISS

GWAV

KULR

LICN

Nuveen Insured California Premium Fund Ii

PPIH

SKIL

SMXT

12 Industrials Stocks Moving In Wednesday's Intraday Session

Deep-pocketed investors have adopted a bullish approach towards MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in MDB usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 18 extraordinary options activities for MongoDB. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 50% leaning bullish and 33% bearish. Among these notable options, 11 are puts, totaling $373,310, and 7 are calls, amounting to $191,910.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $320.0 to $440.0 for MongoDB during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in MongoDB's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to MongoDB's substantial trades, within a strike price spectrum from $320.0 to $440.0 over the preceding 30 days.
<h3>MongoDB Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713976289_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MDB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/03/24</td>
<td>$10.6</td>
<td>$10.15</td>
<td>$10.15</td>
<td>$360.00</td>
<td>$70.0K</td>
<td style="text-align: right;">239</td>
<td style="text-align: right;">27</td>
</tr>
<tr>
<td>MDB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$21.2</td>
<td>$20.95</td>
<td>$21.2</td>
<td>$320.00</td>
<td>$38.1K</td>
<td style="text-align: right;">100</td>
<td style="text-align: right;">40</td>
</tr>
<tr>
<td>MDB</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$60.55</td>
<td>$59.85</td>
<td>$59.85</td>
<td>$410.00</td>
<td>$35.9K</td>
<td style="text-align: right;">546</td>
<td style="text-align: right;">6</td>
</tr>
<tr>
<td>MDB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/03/24</td>
<td>$13.85</td>
<td>$13.5</td>
<td>$13.85</td>
<td>$365.00</td>
<td>$34.6K</td>
<td style="text-align: right;">53</td>
<td style="text-align: right;">32</td>
</tr>
<tr>
<td>MDB</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$20.4</td>
<td>$20.35</td>
<td>$20.35</td>
<td>$370.00</td>
<td>$34.5K</td>
<td style="text-align: right;">142</td>
<td style="text-align: right;">4</td>
</tr>
</tbody>
</table>

<h3>About MongoDB</h3>
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
<h3>Current Position of MongoDB</h3>
<ul>
<li>With a volume of 644,685, the price of MDB is down -0.9% at $363.01. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 36 days.</li>
</ul>
<h3>Expert Opinions on MongoDB</h3>
A total of 4 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $455.0.
<ul>
<li>An analyst from Needham has revised its rating downward to Buy, adjusting the price target to $465. </li>
<li>An analyst from Tigress Financial persists with their Buy rating on MongoDB, maintaining a target price of $500. </li>
<li>Maintaining their stance, an analyst from Keybanc continues to hold a Overweight rating for MongoDB, targeting a price of $440. </li>
<li>In a cautious move, an analyst from Loop Capital downgraded its rating to Buy, setting a price target of $415. </li>
</ul>
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest MongoDB options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

This Is What Whales Are Betting On MongoDB

<h3>Gainers</h3>
<ul>
<li>ReAlpha Tech Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRE#NASDAQ">AIRE</a>) shares rose 38.6% to $0.84 during Wednesday's regular session. The market value of their outstanding shares is at $36.9 million. As per the news, the Q1 earnings report came out 3 days ago. </li>
<li>NextTrip (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRP#NASDAQ">NTRP</a>) shares rose 38.46% to $3.96. The market value of their outstanding shares is at $5.3 million. </li>
<li>Ribbon Comms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBBN#NASDAQ">RBBN</a>) stock increased by 30.35% to $3.35. The market value of their outstanding shares is at $578.5 million. As per the news, the Q1 earnings report came out today. </li>
<li>Prairie Operating (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROP#NASDAQ">PROP</a>) stock increased by 23.28% to $14.57. The market value of their outstanding shares is at $146.1 million. </li>
<li>Red Cat Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCAT#NASDAQ">RCAT</a>) shares moved upwards by 22.08% to $1.47. The market value of their outstanding shares is at $108.8 million. </li>
<li>MMTEC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTC#NASDAQ">MTC</a>) stock increased by 21.84% to $2.73. The market value of their outstanding shares is at $543.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Brand Engagement Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNAI#NASDAQ">BNAI</a>) shares fell 18.6% to $3.5 during Wednesday's regular session. The market value of their outstanding shares is at $116.6 million. </li>
<li>Cemtrex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CETX#NASDAQ">CETX</a>) shares decreased by 13.66% to $2.15. The market value of their outstanding shares is at $2.2 million. </li>
<li>Teledyne Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDY#NYSE">TDY</a>) stock fell 12.36% to $356.78. The company's market cap stands at $16.9 billion. As per the news, the Q1 earnings report came out today. </li>
<li>Ostin Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OST#NASDAQ">OST</a>) shares decreased by 12.0% to $0.44. The market value of their outstanding shares is at $7.3 million. </li>
<li>BIT Mining (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTCM#NYSE">BTCM</a>) stock decreased by 10.85% to $3.08. The market value of their outstanding shares is at $34.1 million. </li>
<li>Mawson Infra Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIGI#NASDAQ">MIGI</a>) stock decreased by 10.27% to $1.35. The market value of their outstanding shares is at $22.5 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIRE

BNAI

CETX

MAWSON INFRSTRUCTURE GRP by Mawson Infrastructure Group Inc.

MIGI

NTRP

PROP

RBBN

RCAT

12 Information Technology Stocks Moving In Wednesday's Intraday Session

Whales with a lot of money to spend have taken a noticeably bearish stance on American Airlines Gr.
Looking at options history for American Airlines Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>) we detected 11 trades.
If we consider the specifics of each trade, it is accurate to state that 36% of the investors opened trades with bullish expectations and 54% with bearish.
From the overall spotted trades, 6 are puts, for a total amount of $726,530 and 5, calls, for a total amount of $500,960.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $12.0 to $25.0 for American Airlines Gr over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for American Airlines Gr's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across American Airlines Gr's significant trades, within a strike price range of $12.0 to $25.0, over the past month.
<h3>American Airlines Gr Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713976283_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$10.85</td>
<td>$10.3</td>
<td>$10.8</td>
<td>$25.00</td>
<td>$324.0K</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>AAL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$0.55</td>
<td>$0.52</td>
<td>$0.53</td>
<td>$17.00</td>
<td>$265.0K</td>
<td>2.8K</td>
<td>5.0K</td>
</tr>
<tr>
<td>AAL</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$0.88</td>
<td>$0.84</td>
<td>$0.84</td>
<td>$12.00</td>
<td>$210.0K</td>
<td>77.0K</td>
<td>2.5K</td>
</tr>
<tr>
<td>AAL</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/26/24</td>
<td>$0.38</td>
<td>$0.36</td>
<td>$0.37</td>
<td>$14.00</td>
<td>$92.5K</td>
<td>4.3K</td>
<td>2.5K</td>
</tr>
<tr>
<td>AAL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/19/24</td>
<td>$0.88</td>
<td>$0.86</td>
<td>$0.86</td>
<td>$15.00</td>
<td>$64.5K</td>
<td>492</td>
<td>751</td>
</tr>
</tbody>
</table>

<h3>About American Airlines Gr</h3>
American Airlines is the world's largest airline by aircraft, capacity, and scheduled revenue passenger miles. Its major U.S. hubs are Charlotte, Chicago, Dallas/Fort Worth, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C. It generates over 30% of U.S. airline revenue connecting Latin America with destinations in the United States. After completing a major fleet renewal, the company has the youngest fleet of U.S. legacy carriers.
In light of the recent options history for American Airlines Gr, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>American Airlines Gr's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 14,794,287, the AAL's price is down by -1.9%, now at $13.96. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 1 days.</li>
</ul>
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for American Airlines Gr, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Behind the Scenes of American Airlines Gr's Latest Options Trends

Investors with a lot of money to spend have taken a bearish stance on Lucid Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether this is an institution or just a wealthy individual, we don't know. But when something this big happens with LCID, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 13 options trades for Lucid Gr.
This isn't normal.
The overall sentiment of these big-money traders is split between 0% bullish and 100%, bearish.
Out of all of the options we uncovered, 12 are puts, for a total amount of $469,787, and there was 1 call, for a total amount of $27,050.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $5.0 to $5.0 for Lucid Gr over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
In terms of liquidity and interest, the mean open interest for Lucid Gr options trades today is 998.0 with a total volume of 13,461.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Lucid Gr's big money trades within a strike price range of $5.0 to $5.0 over the last 30 days.
<h3>Lucid Gr Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713976278_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LCID</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$2.67</td>
<td>$2.54</td>
<td>$2.67</td>
<td>$5.00</td>
<td>$74.7K</td>
<td style="text-align: right;">131</td>
<td>570</td>
</tr>
<tr>
<td>LCID</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$2.72</td>
<td>$2.58</td>
<td>$2.72</td>
<td>$5.00</td>
<td>$65.0K</td>
<td style="text-align: right;">131</td>
<td>990</td>
</tr>
<tr>
<td>LCID</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$2.67</td>
<td>$2.54</td>
<td>$2.67</td>
<td>$5.00</td>
<td>$42.7K</td>
<td style="text-align: right;">131</td>
<td>750</td>
</tr>
<tr>
<td>LCID</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$2.72</td>
<td>$2.66</td>
<td>$2.72</td>
<td>$5.00</td>
<td>$38.0K</td>
<td style="text-align: right;">131</td>
<td>1.9K</td>
</tr>
<tr>
<td>LCID</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$2.72</td>
<td>$2.66</td>
<td>$2.72</td>
<td>$5.00</td>
<td>$35.3K</td>
<td style="text-align: right;">131</td>
<td>1.3K</td>
</tr>
</tbody>
</table>

<h3>About Lucid Gr</h3>
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.
<h3>Lucid Gr's Current Market Status</h3>
<ul>
<li>With a trading volume of 10,197,903, the price of LCID is up by 0.4%, reaching $2.53.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 12 days from now.</li>
</ul>
<h3>What The Experts Say On Lucid Gr</h3>
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $2.9.
<ul>
<li>An analyst from Citigroup has revised its rating downward to Neutral, adjusting the price target to $2. </li>
</ul>
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Lucid Gr, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Lucid Gr's Options Frenzy: What You Need to Know

UBS analyst Rayna Kumar maintains Visa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) with a Buy and raises the price target from $315 to $325.

Price Target

Analyst Ratings

UBS Maintains Buy on Visa, Raises Price Target to $325

NFLX

Live On CNBC, Steve Weiss Announces Bought More Netflix

UBS analyst Munjal Shah maintains Seagate Tech Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>) with a Neutral and raises the price target from $90 to $95.

UBS Maintains Neutral on Seagate Tech Hldgs, Raises Price Target to $95

RBC Capital analyst Deane Dray maintains Pentair (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNR#NYSE">PNR</a>) with a Outperform and raises the price target from $101 to $103.

RBC Capital Maintains Outperform on Pentair, Raises Price Target to $103

BMO Capital analyst Michael Zaremski maintains WR Berkley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WRB#NYSE">WRB</a>) with a Market Perform and lowers the price target from $93 to $87.

BMO Capital Maintains Market Perform on WR Berkley, Lowers Price Target to $87

UBS analyst Gavin Parsons maintains RTX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) with a Neutral and raises the price target from $103 to $105.

UBS Maintains Neutral on RTX, Raises Price Target to $105

PENN

David Einhorn's Greenlight Capital Confirms New Positions In HP Inc, Penn Entertainment

Cemex shares are trading lower after B of Securities downgraded the stock from Buy to Neutral.

BMO Capital analyst John McNulty reiterates Sherwin-Williams (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>) with a Outperform and lowers the price target from $385 to $377.

BMO Capital Reiterates Outperform on Sherwin-Williams, Lowers Price Target to $377

Genmab (Otc) (GMAB) has released an update. Genmab A/S, the Danish biotechnology firm, has been actively purchasing its shares back and has acquire...

Genmab Advances Share Buy-back Program

In a report released today, Asthika Goonewardene from Truist Financial maintained a Buy rating on Genmab (GMAB – Research Report). The company's sh...

Truist Financial Keeps Their Buy Rating on Genmab (GMAB)

This year, the biotech industry anticipates a resurgence with increased M&A, FDA approvals, and AI-driven innovations. Given the industry's rosy prospects, biotech stocks BioMarin Pharmaceutical (BMRN), ANI Pharmaceuticals (ANIP), and Genmab A/S (GMAB), gaining significant altitude and interest, could be ideal buys. Read on... The biotechnology market is expanding considerably due to government support and increased demand in healthcare and agriculture. Advancements in stem cell technology, DNA fingerprinting, and genetic engineering are further driving market growth.
So, investors could consider investing in top biotech stocks BioMarin Pharmaceutical Inc. (<a href="https://stocknews.com/stock/BMRN/">BMRN</a>), ANI Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/ANIP/">ANIP</a>), and Genmab A/S (<a href="https://stocknews.com/stock/GMAB/">GMAB</a>), gaining momentum and attracting interest.
The biotech industry outlook for <a href="https://www.ropesgray.com/en/insights/alerts/2024/03/life-sciences-2024-dealmaking-trends-and-outlook">2024 is upbeat</a>. Increasing mergers and acquisitions (M&amp;A) and licensing activity, backed by improved public equity markets and ample cash reserves in large pharmaceutical companies and venture capital funds, suggests a potential boost in dealmaking and value creation.
Besides, U.S. FDA approvals surged by <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approvals-bounce-back-2023-sparking-hopes-biotech-recovery-2024-01-02/">nearly 50% in 2023</a> compared to 2022, signaling a potential rebound for the biotech industry. Analysts anticipate increased investment in biotech firms following the uptick in novel drug approvals, though concerns about government scrutiny and high interest rates linger.
Moreover, this year, the biotech industry expects significant growth in targeted protein degradation research and anticipates M&amp;A deals to <a href="https://www.labiotech.eu/in-depth/biotech-trends-2024/#:~:text=beyond%E2%80%8B%E2%80%8B.-,M%26A%20activity%20will%20keep%20going%20strong%20in%202024,%24225%20billion%20to%20%24275%20billion.">reach $225 billion to $275 billion</a>. Meanwhile, AI continues to drive innovations in drug discovery and treatment repurposing, leading to a more precise use of AI in biotech.
Further, the rising demand for AI-driven solutions in drug discovery, accelerated by the pandemic, is reshaping the pharmaceutical industry. The global AI in drug discovery market is expected to expand at a <a href="https://www.marketsandmarkets.com/Market-Reports/ai-in-drug-discovery-market-151193446.html">CAGR of 40.2%</a> to reach $4.90 billion by 2028.
Considering these conducive trends, let's examine the fundamentals of the three <a href="https://stocknews.com/category/biotech/">Biotech</a> stock picks, beginning with the third choice.
Stock #3: BioMarin Pharmaceutical Inc. (<a href="https://stocknews.com/stock/BMRN/">BMRN</a>)
BMRN develops and markets therapies for rare and life-threatening diseases such as mucopolysaccharidosis, phenylketonuria, and hemophilia. Its products target enzyme deficiencies and genetic disorders, offering hope to patients with limited treatment options.
BMRN's revenue has grown at a CAGR of 9.2% over the past three years. Over the same period, the company's <a href="https://www.investopedia.com/terms/e/ebitda.asp">EBITDA</a> has increased at a CAGR of 174.2%.
BMRN's total revenue grew 20.2% year-over-year to $646.21 million in the fourth quarter that ended December 31, 2023. It's income from operations was $14.22 million, compared to the year-ago quarter's loss from operations of $24.50 million. Its non-GAAP net income and EPS increased 50.4% and 48.5% from the prior-year quarter to $94.90 million and $0.49, respectively.
For the fiscal year 2024, BMRN forecasts total revenues between $2.70 billion and $2.80 billion, alongside a non-GAAP EPS ranging from $2.60 to $2.80.
Street expects BMRN's revenue and EPS to grow 14.4% and 36.7% year-over-year to $2.77 billion and $2.84 for the fiscal year ending December 2024, respectively.  The company surpassed the revenue and EPS estimates in three of the trailing four quarters, which is promising.
BMRN's shares have surged 4.6% over the past nine months and 3.5% over the past month to close the last trading session at $88.98. Also, it gained 2% intraday. It is currently trading above its 50-day moving average of $87.38, indicating an uptrend.
BMRN's <a href="https://stocknews.com/powr-ratings/">POWR</a><a href="https://stocknews.com/powr-ratings/"> Ratings</a> reflect this sound outlook. The stock has an overall rating of B, equating to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted optimally.
The stock has a B grade for Growth and Value. In the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry, BMRN is ranked #18 among 360 stocks.
To access additional ratings for BMRN's Momentum, Stability, Sentiment, and Quality, click <a href="https://stocknews.com/stock/BMRN/">here</a>.
Stock #2: ANI Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/ANIP/">ANIP</a>)
ANIP is a biopharmaceutical company that develops, manufactures, and markets prescription pharmaceuticals, including controlled substances, oncology products, and more. The company also provides contract development and manufacturing services and distributes products through various channels.
On April 9, 2024, ANIP launched Baclofen Oral Suspension, a generic version of Fleqsuvy&#xAE;. With U.S. annual sales for Baclofen Oral Suspension totaling approximately $39 million, this move reflects ANIP's entry into a rapidly growing limited-competition market.
ANIP's revenue has grown at a CAGR of 19.3% over the past five years. Over the same period, the company's EBITDA has increased at a CAGR of 9.6%, and its net income and levered FCF have grown at CAGRs of 3.9% and 19.2%, respectively.
During the fourth quarter, which ended December 31, 2023, ANIP's net revenues rose 39.7% year-over-year to $131.65 million. Its operating income amounted to $6.73 million, up 269.6% from the previous-year quarter. Also, non-GAAP net income available to common shareholders and EPS grew 54.3% and 31.6% from the prior-year quarter to $19.20 million and $1, respectively.
The company projects net revenue to be between $520 million and $542 million, adjusted EBITDA ranging from $135 million to $145 million, and adjusted EPS anticipated to be between $4.26 and $4.67. In addition, its net revenue for Cortrophin Gel is estimated to be between $170 million and $180 million.
Analysts expect ANIP's revenue to grow 17.3% year-over-year to $125.27 million for the first quarter that ended March 2024. Its EPS for the same period is expected to be $0.98. The company surpassed the consensus revenue and EPS estimates in each of the trailing four quarters.
Shares of ANIP surged 75.7% over the past year and 28.9% over the past nine months to close the last trading session at $67.05. It is currently trading above its 50-day and 200-day moving averages of $62.95 and $57.89, respectively.
ANIP's POWR Ratings reflect its strong prospects. The stock has an overall rating of B, equating to a Buy in our proprietary rating system.
ANIP has an A grade for Growth and a B for Value and Sentiment. Within the same industry, it is ranked #16.
Click <a href="https://stocknews.com/stock/ANIP/">here</a> for ANIP's additional POWR Ratings for Momentum, Stability, and Quality ratings.
Stock #1: Genmab A/S (<a href="https://stocknews.com/stock/GMAB/">GMAB</a>)
Headquartered in Copenhagen, Denmark, GMAB develops antibody therapeutics primarily in Denmark, with offerings including DARZALEX for cancer treatment, teprotumumab for thyroid eye disease, and Amivantamab for advanced gastric or esophageal cancer.
On March 15, 2024, GMAB launched a share buy-back program from March 18, 2024, to December 16, 2024, allowing the repurchase of up to DKK3.50 billion ($509.53 million) worth of shares through Morgan Stanley Europe SE, per regulatory standards and market conditions, with weekly transaction announcements scheduled.
GMAB's revenue has grown at a CAGR of 40.4% over the past five years. Over the same period, the company's EBITDA has increased at a CAGR of 31%, and its net income and EPS have grown at CAGRs of 24.2% and 22.7%, respectively.
In the fiscal year that ended December 31, 2023, GMAB's revenue increased 13.6% year-over-year to DKK16.47 billion ($2.40 billion). Its operating profit was DKK5.32 billion ($774.64 million), and the company reported a net profit of DKK4.35 billion ($633.57 million).
As of December 31, 2023, its total assets amounted to DKK35.29 billion ($5.14 billion), compared to DKK30.12 billion ($4.38 billion) as of December 31, 2022.
For the fiscal year 2024, the company expects revenue between DKK18.70 billion ($2.72 billion) and DKK20.50 billion ($2.98 billion), with gross profit ranging from DKK18 billion ($2.62 billion) and DKK19.50 billion ($2.84 billion). Also, operating profit is forecasted to be between DKK4.60 billion ($669.67 million) and DKK7.10 billion ($1.03 billion).
For the fiscal year ending December 2024, analysts expect GMAB's revenue and EPS to increase 20.5% and 22.4% year-over-year to $2.86 billion and $1.16, respectively. The company surpassed the revenue estimates in each of the trailing four quarters.
The stock soared marginally intraday to close the last trading session at $29.97. It is currently trading above its 50-day moving average of $29.12.
GMAB's POWR Ratings reflect its robust prospects. The stock has an overall rating of B, equating to a Buy in our proprietary rating system.
GMAB has a B grade for Value and Quality. Within the same industry, it is ranked #11.
Beyond the POWR Ratings highlighted above, we have also rated GMAB for Growth, Momentum, Stability, and Sentiment. Get all GMAB ratings <a href="https://stocknews.com/stock/GMAB/">here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
GMAB shares were trading at $29.63 per share on Wednesday morning, down $0.34 (-1.13%). Year-to-date, GMAB has declined -6.94%, versus a 8.25% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Kritika Sarmah</h2> <img src='https:/wp-content/uploads/2022/08/Kritika-Sarmah_Image-3.jpg' style="float:left; padding:5px;width:125px;">Her interest in risky instruments and passion for writing made Kritika an analyst and financial journalist. She earned her bachelor's degree in commerce and is currently pursuing the CFA program. With her fundamental approach, she aims to help investors identify untapped investment opportunities.<a href="https://stocknews.com/authors/?author=kritika-sarmah">More...</a>The post <a href=https://stocknews.com/news/gmab-bmrn-anip-3-biotech-stocks-gaining-altitude-and-interest/>3 Biotech Stocks Gaining Altitude and Interest</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Biotech Stocks Gaining Altitude and Interest

Genmab (Otc) (GMAB) has released an update. Genmab A/S, a leading biotechnology firm, has been actively purchasing its own shares, with a total val...

J&J sets guidance below consensus as MedTech underperforms

Genmab (Otc) (GMAB) has released an update. Genmab A/S reported robust first quarter sales for 2024, announcing net sales of DARZALEX (daratumumab)...

Genmab Reports Strong Q1 Sales of DARZALEX

Genmab Acquires A Missing Piece For Its Pipeline

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Legend Biotech (LEGN – Research Report), Genmab (GMA...

Analysts Are Bullish on These Healthcare Stocks: Legend Biotech (LEGN), Genmab (GMAB)

Genmab (Otc) (GMAB) has released an update. Genmab A/S, a prominent biotech firm, has been actively executing its share buy-back program, purchasin...

ABBV

ANIP

BMRN

LEGN

LGND

Press Releases

New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)

New Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Shows Strong, Durable Treatment Response for Patients with Difficult-To-Treat Relapsed/Refractory (R/R) Follicular Lymphoma (FL)

TIVDAK® Supplemental Biologics License Application Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical Cancer

TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer

Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer

Genmab Publishes 2023 Annual Report

Genmab Announces Initiation of Share Buy-Back Program

U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma